Literature DB >> 23404488

Oncocytic carcinoma of the parotid gland.

Ming-Wei Huang1, Jian-Guo Zhang, Jie Zhang, Shu-Ming Liu, Lei Zheng, Yan Shi, Dian-Yin Shi, Guang-Yan Yu.   

Abstract

OBJECTIVES/HYPOTHESIS: The incidence of oncocytic carcinoma of the parotid gland is low, so a systematic evaluation of treatment strategies is lacking. We aimed to describe our experiences in treating this malignancy. STUDY
DESIGN: Retrospective study.
METHODS: We reviewed the files for 18 patients (14 males) of oncocytic carcinoma of the parotid gland in our institution from 1991 to 2011. Four patients underwent surgery alone, four surgery and postoperative radiotherapy, nine surgery and postoperative brachytherapy, and one radiotherapy alone. Median follow-up was 36 months (range 2-108 months).
RESULTS: The 5-year local control rate was 66.9%, overall survival 68.6%, disease progression-free survival 46.2%, and 5-year freedom from distant metastasis 61.0%. Clinical N category, local recurrence, and distant metastasis significantly influenced overall survival.
CONCLUSIONS: Conservative parotidectomy is not radical enough to treat oncocytic carcinoma of the parotid gland. Elective neck dissection is recommended for patients with cancer stage T2 to 4. Surgery with postoperative (125) I brachytherapy leads to good local control for patients with advanced disease or with positive or close resection margins.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23404488     DOI: 10.1002/lary.23696

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Oncocytic Carcinoma of the Cranio-Orbital Area: A Case Report.

Authors:  Peng Yang; Libin Jiang; Honggang Liu; Jialiang Zhang; Jun Kang
Journal:  Front Surg       Date:  2022-07-01

2.  The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy: incidence of radioepidermitis and the dose-response relationship.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Lei Zheng; Hong Gao; Jie Zhang; Shu-ming Liu; Ming-wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-09-09       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.